TB-500 research: what the published studies show

Identity and the Actin-Binding Motif

TB-500 is a seven-residue peptide, and its identity as a marketed compound is settled. High-resolution mass spectrometry identified the N-terminal acetylated 17-23 fragment of human thymosin β4, Ac-LKKTETQ, in TB-500.^[1] That identification is also what allows the metabolism work below to be read as evidence about this product rather than about a related molecule.

Those residues correspond to a defined functional site within a larger protein. Thymosin β4 is the full-length 43-residue parent, characterized as the major actin-sequestering molecule in eukaryotic cells.^[2]

A 2010 review maps the parent protein's activities onto discrete short sequences within it.^[3] One is a short sequence containing LKKTETQ: the central actin-binding domain, residues 17-23, plus one additional amino acid.^[3] The review identifies that sequence as promoting angiogenesis, wound healing and cell migration.^[3] That mapping is why a seven-residue peptide is studied in its own right rather than only as part of the protein, and it sets up the direct comparisons below.

A 1996 mutational study mapped the actin binding site in more detail, using chemically synthesized full-length variants rather than the isolated fragment.^[4] It reported two separate structural entities: the N-terminal part at residues 1-16, and a hexapeptide motif at residues 17-22.^[4] Charged and hydrophobic residues in both were identified as participating in the actin interaction.^[4] The model it proposes has the N-terminal part adopting an alpha-helix for actin binding.^[4] That work characterises the parent protein, so read-across to the seven-residue fragment is extrapolated rather than demonstrated.

Direct Comparisons With the Parent Protein

Two studies tested the motif itself against the full-length protein, and these are the studies that examined this sequence rather than its parent.

The first, published in 2003, used migration assays with human umbilical vein endothelial cells and vessel-sprouting assays with chick aortic arches.^[5] Researchers observed near-identical activity at approximately 50 nM for the full-length protein and for the seven-amino-acid actin-binding motif.^[5] Peptides lacking any portion of the motif were inactive.^[5] That deletion series acts as a negative control: activity tracked the motif, not peptide presence. The same study found that adhesion to thymosin β4 was blocked by the seven-amino-acid peptide, which the authors read as identifying the major cell-binding site on the parent molecule.^[5] It is competition identifying a binding site, not the fragment reproducing adhesion.

The second study, also from 2003, used an animal model.^[6] In aged mice with full-thickness dermal wounds, a seven-amino-acid peptide duplicating the actin-binding domain, LKKTETQ, was reported to promote repair comparably to the parent molecule.^[6] That comparison covers the aged arm only. The same study's db/db results are parent-protein results: full-length thymosin β4 was linked to significantly increased wound contracture and collagen deposition, while no difference was observed in keratinocyte migration.^[6]

Neither abstract states the acetylation status of the peptide tested: not the endothelial and sprouting study,^[5] nor the dermal study.^[6]

Metabolism and Detection

Two studies address the acetylated product directly, using neither the parent protein nor an unacetylated analogue.

A 2012 equine doping-control study describes the key ingredient of TB-500 as LKKTETQ with artificial acetylation of the N-terminus.^[7] It developed a method for detecting that peptide and its metabolites in urine and plasma.^[7] Working from horses given a single dose containing 10 mg, researchers confirmed the parent peptide at 0.02 ng/mL in equine plasma and 0.01 ng/mL in equine urine.^[7] They report this as the first identification of TB-500 and its metabolites in post-administration samples from horses.^[7]

A 2024 study mapped the metabolism in more detail, across human serum, several in vitro enzyme systems, and urine from rats given TB-500.^[8] Ac-LK was the primary metabolite, at highest concentration in rats over the 0-6 hour interval.^[8]Ac-LKK was a longer-term metabolite, detectable up to 72 hours.^[8] No cytotoxicity was found for the parent compound or its metabolites.^[8]

Together these give a defined analytical picture of the acetylated peptide. It covers a validated quantification method and confirmation limits in the tens of picograms per millilitre,^[7] plus a named early metabolite and a named long-window one.^[8]

Open Questions

Three questions are open in the published literature.

The first is acetylation. A 2024 study attributes the documented functions of this sequence (actin binding, dermal wound healing, angiogenesis and skin repair) to its unacetylated form, LKKTETQ.^[8] The same study states that the biological effects of TB-500 itself have not been documented.^[8] But the 2003 studies that reported migration, sprouting and dermal repair used synthetic seven-residue peptides whose acetylation status their abstracts do not state.^[5] The two positions are reconcilable only if those peptides were unacetylated, and no source here says whether they were. Whether the acetyl cap changes activity has not been directly tested.

The second is which molecule an effect belongs to. Some effects are associated with this compound on the strength of full-length thymosin β4 work, and those are extrapolated rather than demonstrated for the fragment.^[3]

The third is metabolite attribution. In the 2024 study's fibroblast experiments, only Ac-LKKTE showed significant wound-healing activity versus control.^[8] Its authors suggest that previously reported activity may be due to that metabolite rather than to the parent form.^[8]

A 2026 review of peptides marketed direct to patients lists thymosin β4 and TB-500 as separate entries.^[9] It notes that rigorous human safety data are scarce, with potential for serious harm.^[9] The WADA Prohibited List (wada-ama.org) names "Thymosin-β4 and its derivatives e.g. TB-500" under section S2, Growth Factors and Growth Factor Modulators, which is prohibited at all times.